Bure Equity AB
294.90
SEK
+6.70
(+2.32%)
ISIN
SE0000195810
Return %
Stock
S&P 500
1Y
5.89
14.20
3Y
36.02
81.12
5Y
-26.03
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Henrik Gustaf Blomquist
- Full Time Employees
- 10
- Sector
- Finance
- Industry
- Financial conglomerates
- Address
- Nybrogatan 6 Stockholm AB Sweden 114 34
- IPO Date
- Oct 8, 1993
- Website
- bure.se
- Similar Companies
- Business
- Bure Equity AB (publ) is a Sweden-based investment company that specializes in long-term ownership, development and divestment of listed and unlisted operating companies across diverse sectors including technology, medtech, industrials, cybersecurity, financial services and consultancy; its diversified portfolio features core holdings such as Mycronic, a global leader in production equipment for electronics manufacturing; Vitrolife, which develops advanced solutions for fertility treatment; Yubico, a cybersecurity firm offering YubiKey authentication products; Cavotec, providing automated connection and electrification systems for ports and industrial applications; Xvivo Perfusion, delivering clinically optimized systems for organ transplantation; Ovzon, offering mobile satellite broadband services; Mentice, specializing in endovascular simulation solutions; Allgon, a provider of industrial radio remote controls; Atle Investment Management, which manages funds including Alcur Fonder, First Fondene, Fondita, HealthInvest Partners, Humle Fonder and TIN Fonder; Bure Growth, investing in early-stage companies like BioLamina, My Driving Academy, Nodica Group and ScandiNova Systems; Mentimeter, a SaaS platform for interactive meetings; Mercuri International, Europe's leading sales and leadership training consultancy; and Silex Microsystems, a world-leading MEMS foundry for semiconductors with movable components. Founded in 1992 and headquartered in Stockholm, Bure primarily operates in the Nordic region and broader European developed markets, targeting middle-market, later-stage and growth opportunities in sectors such as healthcare, information technology, communication services, consumer staples and industrials. Recent developments include the completion of a 17.0% stake acquisition in Silex Microsystems for SEK 917M as part of a Swedish consortium in June 2025 to support its growth amid geopolitical shifts; increased ownership in Cavotec to 40.7% via purchase of 5.2M shares for SEK 93M; partial divestments of Ovzon shares totaling approximately SEK 225M reducing stake to 8.2%, and Mycronic shares for SEK 148M; Bure Growth's SEK 13M convertible debenture in BioLamina and divestment of Nodica Group shares; Atle's additional purchase consideration for First Fondene; dividend receipts of SEK 246M including from Mycronic and Vitrolife; and executive changes such as new CEOs at Allgon, Mercuri International and Mentice.